{
    "clinical_study": {
        "@rank": "163180", 
        "arm_group": {
            "arm_group_label": "DTP/HepatitisB/Hib vaccine", 
            "arm_group_type": "Experimental", 
            "description": "Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study was to know the safety of DTP/Hepatitis B and Hib/PRP-T vaccine\n      and immediate reactions within the first 30 minutes after injection."
        }, 
        "brief_title": "The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma)", 
        "completion_date": {
            "#text": "July 2011", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B"
            ]
        }, 
        "detailed_description": {
            "textblock": "This trial was an open-label study, no randomization, and no placebo or control group. Total\n      30 healthy infants (age 6-11 weeks) followed this trial. The safety was assessed within 24\n      hours, 48 hours, 72 hours, and 28 days after injection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Infant 6-11 week of age\n\n          -  Infant born after 37-42 week of pregnancy\n\n          -  Infant weighting more than 2.5 kg at birth\n\n          -  Father, mother or legally acceptable representative properly informed about the study\n             and having signed the informed consent form\n\n          -  Parents commit themselves to comply with the indication of the investigator and with\n             the schedule of the trial\n\n        Exclusion Criteria:\n\n          -  Child concomitantly enroll or schedule to be enroll in another trial\n\n          -  Evolving moderate or severe illness, especially infectious diseases or fever\n             (axillary temperature >=37.5 Celsius on Day 0)\n\n          -  Known history of allergy to any component of the vaccine component (e.g.formaldehyde)\n\n          -  History of uncontrolled coagulopathy or blood disorder contraindicating intramuscular\n             injection\n\n          -  Known history of congenital or acquired immunodeficiency (including HIV infection)\n\n          -  Child who has received in the previous 4 weeks a treatment likely to alter the immune\n             response (intravenous immunoglobulin, blood derived product or long term\n             corticotherapy (>2 minggu)\n\n          -  Other vaccination within the 7 days prior to inclusion with the exception of BCG and\n             poliomyelitis\n\n          -  Any abnormality or chronic disease which according to the investigator might\n             interfere with the assessment of the trial objective\n\n          -  Infant with a known history of diphteria, tetanus, pertussis, Hib, Hepatitis B\n             infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "11 Weeks", 
            "minimum_age": "6 Weeks"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01977196", 
            "org_study_id": "Penta 0111"
        }, 
        "intervention": {
            "arm_group_label": "DTP/HepatitisB/Hib vaccine", 
            "description": "DPT/HepatitisB/Hib vaccine (Bio Farma)", 
            "intervention_name": "DPT/HepatitisB/Hib vaccine", 
            "intervention_type": "Biological", 
            "other_name": "Pentavalent"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "DTB/HB/Hib vaccine", 
            "Infants", 
            "Phase I"
        ], 
        "lastchanged_date": "November 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bandung", 
                    "country": "Indonesia", 
                    "state": "West Java", 
                    "zip": "40161"
                }, 
                "name": "Hasan Sadikin Hospital"
            }
        }, 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 of DTP/Hepatitis B 10ug Hib Vaccine", 
        "overall_official": {
            "affiliation": "Faculty of Medicine UNPAD", 
            "last_name": "Kusnandi Rusmil, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Indonesia: National Agency of Drug and Food Control", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Local and systemic reactions", 
            "measure": "Incidence rate of adverse event of DTP/Hepatitis B/Hib vaccine (Bio Farma)", 
            "safety_issue": "Yes", 
            "time_frame": "30 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01977196"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Local and systemic reaction", 
                "measure": "Incidence rate of adverse event of DTP/Hepatitis B/Hib vaccine (Bio Farma)", 
                "safety_issue": "Yes", 
                "time_frame": "28 hours, 48 hours, 72 hours, 28 days"
            }, 
            {
                "description": "Percentage of infants with increasing antibody", 
                "measure": "To asses the immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "source": "PT Bio Farma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PT Bio Farma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}